Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|3 CitationsRecovery & Healing

Follistatin-344 (FS-344) Dosing Protocol: Myostatin Inhibitor Guide

Also known as: FS-344, FS-315 Precursor, Myostatin & Activin-A Antagonist Peptide

Dose Range
100 mcgResearch range
0Typical research window: 100 mcg150 mcg

Studied in published research — not a medical recommendation. Primary protocol (Short-Pulse 10-Day SubQ / Local Recovery Protocol): 100 mcg once daily, Daily for 10 consecutive days.

Protocol at a Glance
How Often
Daily

Daily for 10 consecutive days

A Typical Run
10 days per cycle

Research-reported range; the linked study used a different dose or units. Standard 1 mg lyophilized vial yields exactly ten 100 mcg daily doses; must be stored refrigerated and handled gently without shaking

How It's Taken
Vial

Subcutaneous or bilateral local intramuscular injection

Evidence
Clinical Trials

Published peer-reviewed research & clinical protocols

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.3 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u6u12u18u24u30u
Low end: 100 mcg4 units

All U-100: 100 units = 1 mL. 50 doses in the vial at the low end.

Track the doses you run

Save Follistatin-344 to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

Phase 2/3 Clinical TrialsTier 2 — Human Phase 1/2 Clinical Data
Pharmacological Class
Autocrine Glycoprotein Myostatin (GDF-8) & Activin-A Neutralizing Antagonist
Administration Route
Under-the-skin injection (Subcutaneous or bilateral local intramuscular injection)
2026 FDA & 503A Status
Active Phase 2/3 human clinical trials in 2026; not yet FDA-approved for commercial prescription or 503A bulk pharmacy compounding. Sold strictly as an analytical laboratory reference standard.
WADA Sport Status
Strictly Prohibited at All Times — WADA Section S4.3 (Myostatin Inhibitors & Activin Receptor IIB Antagonists)
Evidence Tier
Tier 2 — Human Phase 1/2 Clinical Data: Published human Phase 1/2 clinical studies, regional regulatory approval, or controlled human biomarker trials
What is a Peptide?

A short chain of amino acids (2-50) linked by peptide bonds. Smaller than proteins. Your body produces thousands of peptides naturally as signaling molecules that regulate everything from appetite to healing. Therapeutic peptides mimic or enhance these natural signals.

Bottom Line Up Front

Follistatin-344 (FS-344) is an autocrine glycoprotein precursor that binds and neutralizes Myostatin (GDF-8) and Activin A to lift the endogenous brake on skeletal muscle hypertrophy and satellite cell proliferation.

Best evidence for

Myostatin (GDF-8) neutralization and muscle fiber regeneration (AAV1-FS344 human gene therapy & animal models)

Weakest evidence for

Sustained systemic hypertrophy from low-dose subcutaneous peptide injections in healthy adults

Pharma equivalent

None

Studies on file

3 (1 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Follistatin-344 is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

Myostatin (Growth Differentiation Factor-8, GDF-8) acts as a chalone that limits skeletal muscle mass by inhibiting satellite cell proliferation and myoblast differentiation via ActRIIB receptors. Follistatin is a naturally occurring cysteine-rich glycoprotein that wraps around Myostatin and Activin A dimers in a 2:1 stoichiometric complex, blocking receptor binding. The 344-amino-acid isoform (FS-344) yields the circulating 315-AA form (FS-315), which includes an acidic C-terminal tail that prevents indiscriminate binding to cell-surface heparan sulfate proteoglycans (unlike FS-288), making FS-344/315 the preferred isoform for selective skeletal muscle signaling without reproductive/pituitary FSH disruption.

Mechanisms of Action

  • Binds and neutralizes extracellular Myostatin (GDF-8) dimers with picomolar affinity, preventing ActRIIB receptor phosphorylation
  • Antagonizes Activin A and GDF-11 signaling to reduce Smad2/3 catabolic transcription and upregulate mTOR/Akt protein synthesis
  • Stimulates quiescent Pax7+ skeletal muscle satellite cells to proliferate and fuse into damaged myofibers
  • C-terminal acidic domain of FS-344/FS-315 reduces cell-surface heparan sulfate trapping compared to tissue-bound FS-288

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Short-Pulse 10-Day SubQ / Local Recovery Protocol
reported protocol
100 mcg once dailyDaily for 10 consecutive days10 days per cycle (followed by 8–12 weeks off)Subcutaneous or bilateral local intramuscular injectionanimal
Baseline & Mid-Cycle Biomarker Bloodwork Panel

GH / IGF-1 & Glycemic Sensitivity Biomarker Panel (Follistatin-344)

Growth hormone secretagogues and somatomedin analogs directly elevate hepatic IGF-1 and can shift fasting insulin sensitivity via GH counter-regulatory signaling.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

Serum IGF-1 (LC/MS) + Z-Score

Day 0 + Wk 6–8

Why track at baseline: Establishes baseline somatotropic output before pituitary or local IGF-1R stimulation.

Week 6–8 check: Confirm physiological upper-quartile elevation (typically +30% to +80% above baseline) without supraphysiological overshoot (>300 ng/mL).

Fasting Insulin & HOMA-IR

Day 0 + Wk 6–8

Why track at baseline: Pituitary GH pulses promote free fatty acid mobilization, which can transiently reduce peripheral insulin sensitivity.

Week 6–8 check: Keep Fasting Insulin <6–8 uIU/mL; if elevated, enforce strict 2–3 hr pre-bed fasting before GH secretagogue administration.

HbA1c & Fasting Plasma Glucose

Day 0 + Wk 6–8

Why track at baseline: Screens for subclinical prediabetes prior to growth-factor or secretagogue exposure.

Week 6–8 check: Verify stable 90-day glycemic control (HbA1c <5.4% optimal) at Week 6–8.

hs-CRP, Prolactin & CMP

Day 0 + Wk 6–8

Why track at baseline: Checks systemic inflammation, pituitary selectivity (no off-target prolactin/cortisol rise), and hepatic/renal clearance.

Week 6–8 check: Confirm Ipamorelin/CJC/Tesamorelin selectivity with unchanged Prolactin and normal liver transaminases.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

1 Human

Intramuscular delivery of AAV1.CMV.FS344 in patients with Becker muscular dystrophy improved 6-minute walk distance and produced histological muscle fiber regeneration and reduced fibrosis without serious adverse events.

Limitations: Human trial utilized viral vector (AAV1) expression of FS-344 rather than daily subcutaneous recombinant peptide injections.

2015|Molecular Therapy
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Prohibited at all times by WADA under Section S4.3 (Agents preventing Activin receptor IIB activation / Myostatin inhibitors)
  • •Because Activin A also regulates tendon fibroblast remodeling, rapid muscle strength gains without progressive tendon loading can increase tendon strain risk
  • •Full-length recombinant glycoproteins are fragile and expensive to synthesize; verify MW (~35–38 kDa) and purity on third-party COAs
  • •May transiently suppress pituitary FSH if dosed excessively due to Activin neutralization
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get Follistatin-344, baseline labs & clinician oversight.

Compare all verified suppliers ↑
50% OFF AUTO-APPLIEDFrom $0.30/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR
FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.